Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterNo recent work listed

Leonard B. Saltz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8353-4670; OpenAlex author ID A5037120205. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
2
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2000: 1 trial · 2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper

Papers 7

  1. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  2. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  3. Identification of germline genetic mutations in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.29664↗
  4. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0531↗
  5. Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. Co-author PMID 23745160↗
  6. Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Co-author PMID 24147159↗
  7. Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. Co-author PMID 23112885↗

Trials 2

  1. Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Study chair NCT00027638↗
  2. Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Study chair NCT00005860↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 7 shared papers, 2012–2018 · strength 0.28
  2. Kenneth H. Yu · 5 shared papers, 2013–2018 · strength 0.22
  3. Maeve Aine Lowery · 4 shared papers, 2014–2018 · strength 0.19
  4. Ghassan K. Abou‐Alfa · 5 shared papers, 2012–2017 · strength 0.18
  5. David Paul Kelsen · 4 shared papers, 2012–2018 · strength 0.16
  6. Anna M. Varghese · 2 shared papers, 2017–2018 · strength 0.11
  7. Christine A. Iacobuzio–Donahue · 2 shared papers, 2017–2018 · strength 0.11
  8. Zsofia Kinga Stadler · 2 shared papers, 2015–2018 · strength 0.10
  9. Erin E. Salo‐Mullen · 2 shared papers, 2015–2018 · strength 0.10
  10. Ali I. Shamseddine · 3 shared papers, 2012–2013 · strength 0.09
  11. Marinela Capanu · 1 shared paper, 2018 · strength 0.07
  12. İbrahim Halil Şahin · 1 shared paper, 2018 · strength 0.07
  13. Zishuo I. Hu · 1 shared paper, 2018 · strength 0.07
  14. Luis Alberto Diaz · 1 shared paper, 2018 · strength 0.07
  15. Sally Naji Temraz · 2 shared papers, 2012–2013 · strength 0.06
  16. Olca Baştürk · 1 shared paper, 2017 · strength 0.05
  17. Vinod P. Balachandran · 1 shared paper, 2017 · strength 0.05
  18. Danielle C. Glassman · 1 shared paper, 2017 · strength 0.05
  19. Emmet Jordan · 1 shared paper, 2017 · strength 0.05
  20. Brian T. Herbst · 1 shared paper, 2017 · strength 0.05
  21. Gökçe Aşkan · 1 shared paper, 2017 · strength 0.05
  22. Jaclyn Frances Hechtman · 1 shared paper, 2017 · strength 0.05
  23. Peter J. Allen · 1 shared paper, 2017 · strength 0.05
  24. Steven D Leach · 1 shared paper, 2017 · strength 0.05
  25. William R. Jarnagin · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.